Foghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference

Share:
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Sam Agresta, M.D., M.P.H, Chief Medical officer is scheduled to participate in a Leukemias panel discussion at the Cowen 41
st Annual Healthcare Conference at 11:40 a.m. ET on March 3, 2021.
About Foghorn Therapeutics
Foghorn
® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control
® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Fanny Cavali , Sam Agresta , Gregory Kelley , Foghorn Therapeutics Inc , Nasdaq , Chief Medical , Annual Healthcare Conference , Gene Traffic , கேம்பிரிட்ஜ் , கேம்பிரிட்ஜ்ஷைர் , ஒன்றுபட்டது கிஂக்டம் , கிரெகொரி கெலீ , ஃபாக்ஹோர்ந் சிகிச்சை இன்க் , நாஸ்டாக் , தலைமை மருத்துவ , ஆண்டு சுகாதாரம் மாநாடு , கீந் போக்குவரத்து ,